Search clinical trials for: rosiglitazone/metformin

Total 2323 results

J JESUS VENEGAS, MD
Instituto Mexicano del Seguro Social; National Council of Science and Technology...

Completed

Effect of Metformin and Rosiglitazone Over no Diabetic With Metabolic Syndrome Patients.

Insulin Resistance
GlaxoSmithKline

Completed

Study Of AVANDAMET® With Or Without Insulin In Type II Diabetes Mellitus Patients. AVANDAMET® is a Registered Trademark of the GSK Group of Companies.

Diabetes Mellitus, Type 2

Spain, Germany, France, Austria, Italy
GlaxoSmithKline

Completed

AVANDAMET Versus Metformin For Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2

Canada
National Heart, Lung, and Blood Institute (NHLBI)

Completed

Rosiglitazone to Treat Patients With Heart Failure and Glucose Intolerance or Type II Diabetes

Congestive Heart Failure

United States
Wellstat Therapeutics

Completed

Safety and Efficacy Study of PN2034 in Type 2 Diabetes Patients on Concomitant Rosiglitazone and Metformin (or Avandamet)

Type 2 Diabetes Mellitus

United States
National Institute of Allergy and Infectious Diseases...

Completed

Metformin and Rosiglitazone, Alone or in Combination, in HIV-Infected Patients With Insulin and Fat Abnormalities

HIV Infections | Hyperinsulinemia | Lipodystrophy

United States
GlaxoSmithKline

Completed

Efficacy and Safety Study of Rosiglitazone/Metformin Therapy vs Rosiglitazone and Metformin in Type 2 Diabetes Subjects

Diabetes Mellitus, Type 2

United States, Canada, Korea, Republic of, Australia, New Zealand, Mexico, Brazil
GlaxoSmithKline

Completed

Rosiglitazone-Metformin Combination Versus Metformin-Sulfonylurea Combination On Beta-Cell Function In Type 2 Diabetes

Type 2 Diabetes Mellitus
New York Medical College
Albert Einstein College of Medicine; University of Tennessee

Completed

EMPOWIR:Enhance the Metabolic Profile of Women With Insulin Resistance (EMPOWIR)

Obesity | Insulin Resistance | Hyperinsulinemia

United States
University Medical Centre Ljubljana

Completed

Treatment of Hyperglycaemia and Insulin Resistance in HIV Infected Patients

Insulin Resistance

Slovenia
Sanofi

Completed

Insulin Glargine v Rosiglitazone as add-on Therapy in Patients Failing Sulfonylurea and Metformin Combination Therapy

Type 2 Diabetes Mellitus

United States
Novo Nordisk A/S

Completed

Effect of Repaglinide and Metformin Combination Tablet or Rosiglitazone and Metformin in Fixed Dose Combination on Blood Glucose Control in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

United States, Puerto Rico
Aristotle University Of Thessaloniki
University of Athens

Completed

Metabolic Effects of Treatment in Patients With Recently Diagnosed Type 2 Diabetes

Type 2 Diabetes Mellitus

Greece
GlaxoSmithKline

Completed

A Study To Evaluate The Safety And Efficacy Of An Investigational Diabetes Drug In Poorly Controlled Type II Diabetics

Diabetes Mellitus, Type 2

United States, Canada, Korea, Republic of, Australia, New Zealand
Samuel Lunenfeld Research Institute, Mount Sinai...
University of Western Ontario, Canada

Completed

A Lifestyle and Combination Medication Therapy Diabetes Prevention Study

Diabetes | Impaired Glucose Tolerance

Canada
GlaxoSmithKline

Completed

Avandamet Bioequivalence Study Brazil - Fed Administration

Diabetes Mellitus, Type 2

Brazil
GlaxoSmithKline

Completed

24-Hour Glycemia: Rosiglitazone Versus Glimepiride In Type 2 Diabetes

Non-Insulin-Dependent Diabetes Mellitus
GlaxoSmithKline

Completed

Malignancy Meta Analysis for BRL49653

Diabetes Mellitus, Type 2
Novo Nordisk A/S

Completed

Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes (LEAD-4)

Diabetes Mellitus, Type 2 | Diabetes

United States, Canada
Novo Nordisk A/S

Terminated

Efficacy and Safety of Inhaled Pre-prandial Human Insulin in Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

United Kingdom, Netherlands, Austria, Spain, France, Germany, Ireland, Switzerland, Finland
Dr. Milan Gupta
GlaxoSmithKline

Completed

Effects of ROSIglitazone on Inflammatory Markers and Adipokines in Diabetic Patients Using an Angiotensin Receptor Blocker (TELmisartan) - The ROSITEL Study

Type 2 Diabetes Mellitus

Canada
GlaxoSmithKline

Completed

An Open Label, Multi-centre, Non-interventional Post-marketing Surveillance to Monitor the Safety and/or Efficacy of AVANDAMET Between June 2004 and January 2010 (AVANDAMETPMS)

Diabetes Mellitus, Type 2
GlaxoSmithKline

Completed

Diabetes Study With Rosiglitazone Monotherapy Versus Metformin Or Glyburide/Glibenclamide

Diabetes Mellitus, Type 2

United States, Germany, Canada, Belgium, Denmark, Spain, Ireland, Netherlands, United Kingdom, Hungary, Italy, France, Austria, Czechia, Norway, Finland, Sweden
M.D. Anderson Cancer Center
Susan G. Komen Breast Cancer Foundation

Completed

The Impact of Obesity and Obesity Treatments on Breast Cancer

Breast Cancer

United States
Novo Nordisk A/S

Completed

Switch From Metformin Monotherapy to a Bitherapy With Metformin and Repaglinide (REPAMET 2)

Diabetes Mellitus, Type 2 | Diabetes

Belgium
National Center for Research Resources (NCRR)

Completed

A Clinical Trial to Prevent the Complications of Insulin Resistance (Including Type-2 Diabetes)

Diabetes Mellitus | Insulin Resistance

United States
Canadian Heart Research Centre
GlaxoSmithKline

Completed

Avandia™ + Amaryl™ or Avandamet™ Compared With Metformin (AVALANCHE™ Study) (AVALANCHE)

Type 2 Diabetes Mellitus

Canada
GlaxoSmithKline

Completed

Study In Postmenopausal Women With Type 2 Diabetes Looking At Approved Diabetes Drugs And How They Affect Bone Health

Diabetes Mellitus, Type 2

United States, Argentina, Canada, Mexico, Spain, Estonia, Pakistan, Philippines
Pfizer

Terminated

Beta Cell Function Tests Over Time In Patients With T2dm Randomized To Metformin Or Rosiglitazone

Type 2 Diabetes Mellitus

Israel
Novo Nordisk A/S

Terminated

Effect of Inhaled Pre-prandial Human Insulin on Blood Glucose Control in Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

United States
National Institute of Diabetes and Digestive and...

Completed

Treatment Options for Type 2 Diabetes in Adolescents and Youth (TODAY) (TODAY)

Diabetes Mellitus, Type II

United States
Turku University Hospital
SmithKline Beecham

Completed

Effects of Rosiglitazone and Metformin on Metabolism in Type 2 Diabetes (ROSI)

Type 2 Diabetes | Insulin Sensitivity

Finland
GlaxoSmithKline

Completed

Prescription Patterns, Resource Utilization & Costs - Add-on Therapy With Anti Dipeptidyl Peptidase-IVs vs Rosiglitazone

Diabetes Mellitus, Type 2
GlaxoSmithKline

Completed

RECORD: Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes (RECORD)

Diabetes Mellitus, Type 2

Spain, Finland, Bulgaria, Belgium, Sweden, Denmark, Germany, Australia, Hungary, Italy, New Zealand, Russian Federation, Ukraine, Estonia, Slovakia, France, Greece, Poland, United Kingdom, Czech Republic, Netherlands, Croatia, Lithu... and more
Solvay Pharmaceuticals

Completed

A Methodological Study To Evaluate The Effects of Single Oral Doses Of Pioglitazone 45 mg And Rosiglitazone 8 mg On Sodium Balance In Healthy Male Volunteers

Type 2 Diabetes Mellitus

United Kingdom
AstraZeneca

Completed

A Study Assessing Saxagliptin Treatment in Type 2 Diabetic Subjects Who Are Not Controlled With TZD Therapy Alone

Diabetes Mellitus, Type 2

United States, Argentina, Canada, Puerto Rico, Mexico, Philippines, India, Peru
Merck Sharp & Dohme LLC

Completed

Safety/Efficacy of Sitagliptin in Patient w/ Type 2 Diabetes (0431-801)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC

Completed

Sitagliptin Metformin/PPARg Agonist Combination Therapy Add-on (0431-052)

Type 2 Diabetes Mellitus
Centre Hospitalier Universitaire Dijon

Completed

Influence of Glitazones on the Vasodilatory Effect of High-density Lipoprotein (HDL) Lipoproteins

Type 2 Diabetes

France
Solvay Pharmaceuticals

Terminated

Fenofibrate and Metformin Fixed Combination vs Rosiglitazone - FAME ROSI

Dyslipidemia | Glucose Metabolism Disorder

Poland, Croatia, Finland, France, Germany, Netherlands, Romania, Ukraine
Aristotle University Of Thessaloniki

Completed

Diagnosis and Therapy of Vulnerable Atherosclerotic Plaque

Stroke | Metabolic Syndrome | Type 2 Diabetes | Carotid Atherosclerosis

Greece
GlaxoSmithKline

Completed

Efficacy and Safety In Poorly Controlled Type 2 Diabetics

Diabetes Mellitus, Type 2
GlaxoSmithKline

Completed

A Study Of BRL49653C For The Treatment Of Type 2 Diabetes

Diabetes Mellitus, Type 2
GlaxoSmithKline

Completed

Fluid Retention in Rosiglitazone Treated Subjects With Autonomic Neuropathy.

Neuropathy, Diabetic

Netherlands
Medstar Health Research Institute
GlaxoSmithKline

Terminated

Ppar-Gamma EliminAtes Restenosis Longevity Study: PEARLS

Metabolic Syndrome

United States
Baskent University

Completed

Effects of Rosiglitazone on Serum Ghrelin and Peptide YY Levels

Obesity | Type 2 Diabetes Mellitus

Turkey
Valme University Hospital

Completed

Treatment Insulin Resistence in HCV G-1 Patient (TRIC-1)

Chronic Hepatitis C

Spain
GlaxoSmithKline

Completed

Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy In Subjects With Mild To Moderate Alzheimer's Disease (REFLECT-3)

Alzheimer's Disease

United States, Australia, Spain, Bulgaria, Poland, Germany, Philippines, Singapore, Belgium, Canada, Hong Kong, Korea, Republic of, Finland, Slovenia, Czechia, France, South Africa, Sweden, Netherlands, Malaysia, United Kingdom, S...
Institute for Clinical and Experimental Medicine

Completed

Cardioprotective and Metabolic Effects of Metformin in Patients With Heart Failure and Diabetes (CARMET)

Insulin Resistance | Chronic Heart Failure

Czechia
Hospital Authority, Hong Kong

Unknown

Targeting Peroxisome Proliferator-activated Receptor-gamma in Peritoneal Dialysis Patients - Will it Reduce Inflammation, Atherosclerosis, Calcification and Improve Survival of Peritoneal Dialysis Patients?

Cardiovascular Diseases | Kidney Diseases | Chronic Disease

China

Search clinical trials for: rosiglitazone/metformin

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Iran

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations